Insider Selling: Matthew Plunkett Sells 12,000 Shares of Cell Therapeutics Stock (CTIC)
Cell Therapeutics (NASDAQ:CTIC) EVP Matthew Plunkett sold 12,000 shares of the stock on the open market in a transaction that occurred on Monday, July 7th. The stock was sold at an average price of $2.89, for a total value of $34,680.00. Following the transaction, the executive vice president now directly owns 584,904 shares of the company’s stock, valued at approximately $1,690,373. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Cell Therapeutics (NASDAQ:CTIC) opened at 2.709 on Thursday. Cell Therapeutics has a one year low of $1.01 and a one year high of $4.25. The stock has a 50-day moving average of $2.95 and a 200-day moving average of $3.13. The company’s market cap is $385.1 million.
Cell Therapeutics (NASDAQ:CTIC) last issued its quarterly earnings data on Tuesday, April 29th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.03. The company had revenue of $1.40 million for the quarter, compared to the consensus estimate of $1.10 million. On average, analysts predict that Cell Therapeutics will post $-0.60 earnings per share for the current fiscal year.
Separately, analysts at Ladenburg Thalmann initiated coverage on shares of Cell Therapeutics in a research note on Thursday, May 22nd. They set a “buy” rating and a $6.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Cell Therapeutics currently has a consensus rating of “Buy” and an average price target of $4.83.
Cell Therapeutics, Inc develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.